Your browser doesn't support javascript.
loading
Mechanism of Action of an EPAC1-Selective Competitive Partial Agonist.
Shao, Hongzhao; Mohamed, Hebatallah; Boulton, Stephen; Huang, Jinfeng; Wang, Pingyuan; Chen, Haiying; Zhou, Jia; Luchowska-Stanska, Urszula; Jentsch, Nicholas G; Armstrong, Alison L; Magolan, Jakob; Yarwood, Stephen; Melacini, Giuseppe.
Afiliação
  • Wang P; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
  • Chen H; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
  • Zhou J; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
  • Luchowska-Stanska U; Institute of Biological Chemistry, Biophysics and Bioengineering, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh Campus, Edinburgh EH14 4AS, United Kingdom.
  • Yarwood S; Institute of Biological Chemistry, Biophysics and Bioengineering, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh Campus, Edinburgh EH14 4AS, United Kingdom.
J Med Chem ; 63(9): 4762-4775, 2020 05 14.
Article em En | MEDLINE | ID: mdl-32297742
ABSTRACT
The exchange protein activated by cAMP (EPAC) is a promising drug target for a wide disease range, from neurodegeneration and infections to cancer and cardiovascular conditions. A novel partial agonist of the EPAC isoform 1 (EPAC1), I942, was recently discovered, but its mechanism of action remains poorly understood. Here, we utilize NMR spectroscopy to map the I942-EPAC1 interactions at atomic resolution and propose a mechanism for I942 partial agonism. We found that I942 interacts with the phosphate binding cassette (PBC) and base binding region (BBR) of EPAC1, similar to cyclic adenosine monophosphate (cAMP). These results not only reveal the molecular basis for the I942 vs cAMP mimicry and competition, but also suggest that the partial agonism of I942 arises from its ability to stabilize an inhibition-incompetent activation intermediate distinct from both active and inactive EPAC1 states. The mechanism of action of I942 may facilitate drug design for EPAC-related diseases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Fatores de Troca do Nucleotídeo Guanina Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Fatores de Troca do Nucleotídeo Guanina Idioma: En Ano de publicação: 2020 Tipo de documento: Article